# China NMPA Inspection - Jiangxi Pinxin Pharmaceutical Co., Ltd. - September 11, 2015

Source: https://www.globalkeysolutions.net/records/china_inspection/jiangxi-pinxin-pharmaceutical-co-ltd/49e21d52-ab35-4403-a789-7129ffe91162/
Source feed: China

> China NMPA unannounced inspection for Jiangxi Pinxin Pharmaceutical Co., Ltd. published September 11, 2015. The Jiangxi Provincial Food and Drug Administration conducted unannounced inspections of eight drug wholesale enterprises in August 2015, adhering to 

---

## Details

- Record Type: CHINA_INSPECTION
- Title: Announcement on the Handling of Unannounced Inspections of Drug Distribution in Jiangxi Province (No. 2, 2015)
- Company Name: Jiangxi Pinxin Pharmaceutical Co., Ltd.
- Publication Date: 2015-09-11
- Product Type: Drugs
- Summary: The Jiangxi Provincial Food and Drug Administration conducted unannounced inspections of eight drug wholesale enterprises in August 2015, adhering to the 2015 Drug Distribution Surprise Inspection Plan. The inspections aimed to ensure compliance with quality and distribution standards. 

Significant issues were identified across several companies. Jiangxi Ruimin Pharmaceutical Co., Ltd. faced severe violations, including the absence of key quality personnel, an unstaffed quality department head and quality control, and cool storage temperature exceeding standards. Consequently, its Good Supply Practice (GSP) certification certificate was revoked. 

Other companies also displayed non-compliance. Jiangxi Hongxing Pharmaceutical Co., Ltd. and Jiangxi Fengcheng Pharmaceutical Co., Ltd. had incomplete temperature records and failed to verify cold storage equipment. Jiangxi Xinyuan Pharmaceutical Co., Ltd. and Jiangxi New Era Pharmaceutical Co., Ltd. had issues with quality personnel availability and staff understanding of duties, respectively. Jiangxi Guangling Pharmaceutical Co., Ltd. lacked comprehensive quality objective implementation and pre-job training. Ruichang Pharmaceutical Co., Ltd. failed to conduct internal audits following leadership changes and had incomplete transport records. Most of these companies were ordered to rectify their identified deficiencies within a specified period. Jiangxi Xinhuiyu Pharmaceutical Co., Ltd. was largely compliant. 

Local Food and Drug Administrations were instructed to oversee the rectification processes and ensure adherence to regulatory requirements, with specific oversight for Jiangxi Ruimin's GSP revocation.

Company: https://www.globalkeysolutions.net/companies/jiangxi-pinxin-pharmaceutical-co-ltd/bdb1ef72-0c91-401f-9c5b-1a9deab9a631/